DEFA14A ·Filed Apr 7, 2026

GERN

GERON CORP
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago SEC0000886744-26-000025
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine filing for an upcoming annual meeting. The key development is the addition of two new directors, which may be of interest to governance-focused investors. No immediate trading action is suggested based on this filing alone.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
GERN ▼ -20.47% at T+60d
NEUTRAL call ✗ call lost -20.47% · α vs SPY -30.92% · entry $1.71 → $1.36
Entry anchored
Apr 7, 03:59 PM ET
via exchange tick
T+1d
+2.92%
call +2.92% · α +2.35%
$1.76
settled 6mo ago
T+5d
-1.17%
call -1.17% · α -4.69%
$1.69
settled 6mo ago
T+20d
-3.51%
call -3.51% · α -12.05%
$1.65
settled 5mo ago
T+60d
-20.47%
call -20.47% · α -30.92%
$1.36
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Geron Corporation has filed its definitive proxy statement (DEFA14A) ahead of its 2026 Annual Meeting, following the recent appointment of two new directors, Patricia S. Andrews and Constantine Chinoporos, as disclosed in an 8-K filing. The proxy materials detail the board's nominees, compensation, and governance practices, with no indication of an activist campaign or contested vote.

Key Facts

  • Filed a DEFA14A proxy statement for the 2026 Annual Meeting of Stockholders.
  • Recent 8-K filing (March 26, 2026) announced the appointment of two new directors, Patricia S. Andrews and Constantine Chinoporos, to the Board.
  • The proxy statement is for routine director elections and corporate governance matters.
  • No activist campaign or contested vote is indicated in the filing.

Financial Impact

No direct financial impact from this routine filing.

governanceboard composition

Risk Factors

  • Routine filing with no immediate financial or strategic implications.
  • Potential for future governance changes as new directors integrate.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0000886744-26-000025
Document: 0000886744-26-000025-index-headers.html0000886744-26-000025
Document: 0000886744-26-000025-index.html0000886744-26-000025
Document: 0000886744-26-000025.txt0000886744-26-000025
4 reports for GERN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for GERN — sortable, filterable
TypeNow
Apr 22, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$1.55 $1.44▼ −7.10%▼ −11.88%$1.22 (−21.61%)
Apr 7, 2026
25w ago
DEFA14A
NEUTRAL ★ 3/10
$1.71 $1.36▼ −20.47%▼ −30.92%$1.22 (−28.95%)
Mar 30, 2026
26w ago
Court Ruling
NEUTRAL ★ 2/10
$1.41 $1.37▼ −2.84%▼ −19.33%$1.22 (−13.83%)
Feb 25, 2026
31w ago
8-K
BULLISH ★ 7/10
$1.72 $1.26▼ −26.74%▼ −33.69%$1.22 (−29.36%)
Showing 4 of 4

US Market Status

Market Open — Closes in 2h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access